Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Short Interest Update

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 40,313 shares, an increase of 29.1% from the December 15th total of 31,224 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average trading volume of 25,648 shares, the days-to-cover ratio is currently 1.6 days. Based on an average trading volume of 25,648 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.1% of the shares of the stock are sold short.

Institutional Trading of Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Optiver Holding B.V. acquired a new stake in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 5,356 shares of the company’s stock, valued at approximately $101,000. 38.81% of the stock is currently owned by hedge funds and other institutional investors.

Nanobiotix Stock Performance

NBTX stock traded down $0.18 during mid-day trading on Monday, hitting $20.99. 13,553 shares of the company were exchanged, compared to its average volume of 34,376. Nanobiotix has a 1-year low of $2.95 and a 1-year high of $30.35. The firm’s 50 day simple moving average is $21.57 and its 200 day simple moving average is $15.79.

Analysts Set New Price Targets

NBTX has been the subject of a number of research analyst reports. Leerink Partners reaffirmed an “outperform” rating on shares of Nanobiotix in a report on Tuesday, November 25th. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a research report on Tuesday, November 4th. Wall Street Zen raised shares of Nanobiotix to a “hold” rating in a research note on Saturday, October 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Nanobiotix currently has an average rating of “Hold” and a consensus price target of $11.00.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.